GlassScriptPhysician profile
David Clemons
NPI 1831683044
$1,298.11
in general payments reported to CMS, 2019-2025
23 companies · $591 in 2025
The $591 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.97 · 2022: $148 · 2024: $546 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $255.02 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $172.23 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $169.28 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $109.01 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Exact Sciences Corporation | $77.90 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $69.21 | 2025 | |
| Agios Pharmaceuticals, INC. | $51.10 | 2025 | Pyrukynd |
| Amgen INC. | $46.44 | 2024 | Repatha, Otezla |
| Novo Nordisk INC | $46.08 | 2024-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $35.49 | 2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $30.21 | 2025 | |
| Insmed, INC. | $29.68 | 2025 | Arikayce |
| Merck Sharp & Dohme LLC | $28.52 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Lundbeck LLC | $20.61 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $20.30 | 2025 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $20.19 | 2024 | Heplisav-B |
| Madrigal Pharmaceuticals | $20.18 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $19.99 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.68 | 2025 | |
| Inspire Medical Systems, INC. | $18.29 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.53 | 2024 | Xifaxan |
| Gilead Sciences, INC. | $12.97 | 2021 | |
| Chiesi USA, INC. | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Clemons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.